HSCS (43) LFWD (46) COCH (42) MYO (37) ⌘ Pro Terminal →

Milestone Scientific Inc. (MLSS) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell MLSS stock right now?

Milestone Scientific Inc. (MLSS) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at 5x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is MLSS's 12-month price target and RQD AI Jury consensus?

MLSS's 12-month base price target is $0.3 (range $0.23 to $0.61), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.32 -0.54% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.32

Milestone Scientific Inc. (MLSS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $28.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.32 (-0.29%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLSS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY MLSS SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.35-5.7% Next Q

Q2 (-2Q)

Grade D$0.33-6.1% Next Q

Q3 (-1Q)

Grade D$0.31+3.2% Next Q

Current

Grade D-$0.32-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MLSS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MLSS currently carries a cautious 43/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.40) and Max Pain ($0.34) forces dealer call-delta covering toward $0.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MLSS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MLSS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

31.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE28% OF RANGE

L: $0$0.32H: $1

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on MLSS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 71.4% gross margin and -10.27% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

20/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like MLSS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLSS)

✓Walkthrough of MLSS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MLSS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.23%📐 HORIZONTAL RANGE

2026-10-30O $0.33H $0.33L $0.30C $0.32VOL 42.0K

RES: $0.66SUP: $0.29SMA50: $0.40SMA200: $0.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLSS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLSS Butterfly Map → + Track MLSS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-14.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MLSS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLSS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MLSS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLSS)

Health Care Rank #557 of 1016 ⚔️ HSCS vs MLSS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLSS vs. HSCS, LFWD, COCH, MYO)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Milestone Scientific Inc. (MLSS) ranks #557 by composite RQD confidence (43/100, grade D-) and #809 by equity capitalization ($28.6M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while MLSS leads on capital efficiency and profitability with -35.0% ROIC and 71.4% gross margin. LFWD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MLSS at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MLSS ACTIVE Milestone Scientific Inc.	D-	43/100	5.0x	71.4%	-35.0%	-0.54%	$28.6M	Benchmark Subject
HSCS HeartSciences Inc.	D-	43/100	—	59.1%	-35.0%	+7.12%	$17.5M	/hscs-vs-mlss →
LFWD Lifeward Ltd.	D	46/100	—	96.0%	-35.0%	+2.78%	$16.7M	/lfwd-vs-mlss →
COCH Envoy Medical Inc. (Class A)	D-	42/100	—	-30.0%	-35.0%	-2.40%	$50.3M	/coch-vs-mlss →
MYO Myomo Inc.	D-	37/100	—	65.7%	-35.0%	+3.18%	$51.5M	/myo-vs-mlss →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000855683

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported GAAP revenue of $9.0M (+4.0% vs. FY2024 revenue of $8.6M ) , GAAP net income of $5.7M, operating cash flow of -$2.9M, and free cash flow of -$2.9M (-0.1% YoY). On the balance sheet, MLSS closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.0M	$5.7M	-$2.9M	-$2.9M	$7.8M	—
FY2024 (FY)	2024-12-31	$8.6M	$4.7M	-$2.9M	-$2.9M	$9.8M	—
FY2023 (FY)	2023-12-31	$0	$6.9M	-$5.3M	-$5.3M	—	—

3. MLSS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.32 (-0.54% 1D, market cap $28.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, MLSS ranks #557 in composite RQD confidence.

How does MLSS compare to HSCS and LFWD in the Health Care sector?

Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (43/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and LFWD (Lifeward Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MLSS?

Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MLSS trading relative to its 50-day, 200-day, and 52-week technical levels?

MLSS last traded at $0.32 (-0.54% on volume of 263,513 shares), positioning the stock -20.00% below its 50-day simple moving average ($0.40) and -8.57% below its 200-day simple moving average ($0.35). Across its 52-week range of $0.22 to $0.58, MLSS sits at the 27.8% percentile with a 14-day RSI of 31.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.36).

MLSS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MLSS stock right now?

Milestone Scientific Inc. (MLSS) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at 5x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MLSS's 12-month price target and RQD AI Jury consensus?

MLSS's 12-month base price target is $0.3 (range $0.23 to $0.61), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MLSS RQD Cockpit MLSS 12M Forecast MLSS Earnings & Move MLSS Dividends & DRIP MLSS Insiders & 13F MLSS Whale Options MLSS Profit Sankey MLSS News & Why